ONO-7746
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-Induced Thrombocytopenia
Conditions
Chemotherapy-Induced Thrombocytopenia
Trial Timeline
May 1, 2011 → —
NCT ID
NCT01345214About ONO-7746
ONO-7746 is a phase 1 stage product being developed by Ono Pharmaceutical for Chemotherapy-Induced Thrombocytopenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01345214. Target conditions include Chemotherapy-Induced Thrombocytopenia.
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy-Induced Thrombocytopenia were approved
Approved (3) Terminated (4) Active (14)
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01345214 | Phase 1 | Terminated |
Competing Products
20 competing products in Chemotherapy-Induced Thrombocytopenia